2021. Roflumilast (Daliresp®) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial. Sarcoidosis, Vasculitis and Diffuse Lung Diseases. 38, 3 (Sep. 2021), e2021035. DOI:https://doi.org/10.36141/svdld.v38i3.11684.